The significance of plasma biomarkers in predicting heart failure among patients with acute myocardial infarction
Plasma Biomarkers Predicting Heart Failure Post Heart Attack
Abstract
Background: Acute myocardial infarction (AMI) is characterized by high mortality and disability rates. Timely and effective revascularization has saved the lives of many patients. However, some patients develop complications such as heart failure (HF) following myocardial infarction, which significantly affects their quality of life and may even be life-threatening. Therefore, the search for effective biomarkers to predict the occurrence of HF after AMI, along with early prevention and treatment strategies, will greatly improve clinical outcomes for patients with post-myocardial infarction HF
Methods: A total of 170 patients with acute myocardial infarction (AMI) were enrolled in this study, including 44 patients with post-AMI heart failure (HF) and 126 patients with post-AMI non-HF. We measured the serum biomarkers NT-proBNP, cTNT, PLR, NLR, and GDF-15 in all patients using enzyme-linked immunosorbent assay (ELISA). Subsequently, we performed t-tests to assess the predictive value of these biomarkers for post-AMI heart failure (HF).
Results: In the group of HF patients, cTNT, NT-proBNP, GDF-15 and NLR was significantly higher than in the group without HF, but PLR was not .The AUC of NLR to predict HF after AMI was 0.632 (95%CI:0.542-0.723), P=0.010, with a cut-off value of (3.86×109)/L , GDF-15 was 0.661 (95%CI0.560-0.763), P=0.002, with a cut-off value of 1.35 ng/mL, and NT-proBNP was 0.82 (95%CI0.723-0.876), P<0.001, with a cut-off value of 1444 pg/mL.
Conclusions: In five biomarkers, there is predictive value in NT-proBNP , NLR, GDF-15 for patients with HF after AMI .
References
2. Segev A, Strauss BH, Tan M, Mendelsohn AA, Lai K, Ashton T, et al. Prognostic significance of admission heart failure in patients with non-ST-elevation acute coronary syndromes (from the Canadian Acute Coronary Syndrome Registries). Am J Cardiol 2006; 98(4): 470-3.
3. Sulo G, Igland J, Vollset SE, Nygard O, Ebbing M, Sulo E, et al. Heart Failure Complicating Acute Myocardial Infarction; Burden and Timing of Occurrence: A Nation-wide Analysis Including 86 771 Patients From the Cardiovascular Disease in Norway (CVDNOR) Project. J Am Heart Assoc 2016; 5(1): e002667.
4. Mogensen UM, Kober L, Jhund PS, Desai AS, Senni M, Kristensen SL, et al. Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. Eur J Heart Fail 2018; 20(3): 514-22.
5. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376(9744): 875-85.
6. McMurray J, DeMets DL, Inzucchi SE, Kober L, Kosiborod MN, Langkilde AM, et al. The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. Eur J Heart Fail 2019; 21(11): 1402-11.
7. Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. New Engl J Med 2020; 382(20): 1883-93.
8. Berezin AE, Berezin AA. Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers. Dis Markers 2020; 2020: 1215802.
9. El NA, Hochadel M, Zahn R, Schneider A, Thiele H, Darius H, et al. Outcomes After Left Main Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock (from the German ALKK PCI Registry). Am J Cardiol 2023; 197: 77-83.
10. Hung J, Teng TH, Finn J, Knuiman M, Briffa T, Stewart S, et al. Trends from 1996 to 2007 in incidence and mortality outcomes of heart failure after acute myocardial infarction: a population-based study of 20,812 patients with first acute myocardial infarction in Western Australia. J Am Heart Assoc 2013; 2(5): e000172.
11. Taniguchi T, Shiomi H, Morimoto T, Watanabe H, Ono K, Shizuta S, et al. Incidence and Prognostic Impact of Heart Failure Hospitalization During Follow-Up After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction. Am J Cardiol 2017; 119(11): 1729-39.
12. Gerber Y, Weston SA, Berardi C, McNallan SM, Jiang R, Redfield MM, et al. Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: a community study. Am J Epidemiol 2013; 178(8): 1272-80.
13. Brunner-La RH, Sanders-van WS. Natriuretic Peptides in Chronic Heart Failure. Card Fail Rev 2019; 5(1): 44-9.
14. Lyngbakken MN, Rosjo H, Holmen OL, Dalen H, Hveem K, Omland T. Temporal Changes in Cardiac Troponin I Are Associated with Risk of Cardiovascular Events in the General Population: The Nord-Trondelag Health Study. Clin Chem 2019; 65(7): 871-81.
15. Uthamalingam S, Patvardhan EA, Subramanian S, Ahmed W, Martin W, Daley M, et al. Utility of the neutrophil to lymphocyte ratio in predicting long-term outcomes in acute decompensated heart failure. Am J Cardiol 2011; 107(3): 433-8.
16. Wollert KC. Growth-differentiation factor-15 in cardiovascular disease: from bench to bedside, and back. Basic Res Cardiol 2007; 102(5): 412-5.
17. Bettencourt P, Ferreira-Coimbra J, Rodrigues P, Marques P, Moreira H, Pinto MJ, et al. Towards a multi-marker prognostic strategy in acute heart failure: a role for GDF-15. Esc Heart Fail 2018; 5(6): 1017-22.
18. Myrmel G, Steiro OT, Tjora HL, Langorgen J, Bjorneklett R, Skadberg O, et al. Growth Differentiation Factor 15: A Prognostic Marker in Patients with Acute Chest Pain without Acute Myocardial Infarction. Clin Chem 2023; 69(6): 649-60.
19. Olivier A, Girerd N, Michel JB, Ketelslegers JM, Fay R, Vincent J, et al. Combined baseline and one-month changes in big endothelin-1 and brain natriuretic peptide plasma concentrations predict clinical outcomes in patients with left ventricular dysfunction after acute myocardial infarction: Insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Int J Cardiol 2017; 241: 344-50.
20. Yan L, Zhang Y, Zhang W, Deng SQ, Ge ZR. lncRNA-NRF is a Potential Biomarker of Heart Failure After Acute Myocardial Infarction. J Cardiovasc Transl 2020; 13(6): 1008-15.
21. Zheng M, Du X, Zhao L, Sun H, Chen M, Yang X. Elevated plasma Sirtuin2 level predicts heart failure after acute myocardial infarction. J Thorac Dis 2021; 13(1): 50-9.
22. Raskovalova T, Twerenbold R, Collinson PO, Keller T, Bouvaist H, Folli C, et al. Diagnostic accuracy of combined cardiac troponin and copeptin assessment for early rule-out of myocardial infarction: a systematic review and meta-analysis. Eur Heart J-Acute Ca 2014; 3(1): 18-27.
Copyright (c) 2024 Guihong Rong, Xiao Wang, Xinling Qin, Yanxia Wang, Meilian Quan, Chunfeng Xi
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.